鼻腔艾司氯胺酮治疗难治性抑郁的安慰剂与抗抑郁应答性别差异
该研究汇总五项随机双盲安慰剂对照试验,分析出生时性别对鼻腔艾司氯胺酮治疗难治性抑郁的总体及症状维度应答影响。艾司氯胺酮在男女均改善MADRS总分,但女性在试验末总体改善及治疗应答率更高,且悲伤与疏离维度改善更明显;男性仅在艾司氯胺酮第2天悲伤症状显著减轻。
要点
- 女性在安慰剂和艾司氯胺酮组试验末MADRS总分改善及应答率均高于男性。
- 女性在试验末悲伤与疏离维度、第15天神经植物性症状改善更显著,与治疗组无关。
- 男性仅在艾司氯胺酮第2天显示悲伤症状显著减轻。
核心结论
- 出生时性别影响难治性抑郁患者对鼻腔艾司氯胺酮及安慰剂的总体应答和症状改善轨迹。
研究设计与样本
- 汇总五项随机双盲安慰剂对照试验,成人难治性抑郁患者每周两次鼻腔艾司氯胺酮或安慰剂联合新启口服抗抑郁药,持续四周。
主要发现
- 艾司氯胺酮改善男女MADRS总分。
- 女性在试验末MADRS总分改善及治疗应答率高于男性,安慰剂和艾司氯胺酮组均如此。
- 女性试验末悲伤与疏离维度改善更明显,第15天神经植物性症状改善更明显,与治疗组无关。
- 男性艾司氯胺酮第2天悲伤症状显著减轻。
关键数值与推荐
- 采用蒙哥马利-艾斯伯格抑郁评定量表(MADRS)总分及悲伤、消极思维、疏离、神经植物性症状四因子评估。
- 评估临床应答率和缓解率。
临床怎么用
- 难治性抑郁治疗策略应考虑出生时性别以优化精准精神科医疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Esketamine has emerged as a fast-acting antidepressant option for individuals with treatment-resistant depression (TRD). Yet, little is known about how sex-assigned-at-birth shapes symptom-specific responses to these interventions, a critical gap in the move toward precision psychiatry. To address this gap, we conducted a pooled analysis of five randomized, double-blind, placebo-controlled trials in which adults with TRD received intranasal esketamine or placebo twice weekly for four weeks, alongside a newly initiated oral antidepressant. We evaluated the effects of sex-assigned-at-birth on overall depression severity, measured via total Montgomery-Åsberg Depression Rating Scale (MADRS) scores, across four symptom factors: sadness, negative thoughts, detachment, and neurovegetative symptoms, and rates of clinical response and remission. Esketamine treatment improved total MADRS scores in both sexes. However, females showed greater improvement in total MADRS scores and higher odds of treatment-response than males towards the end of the trials, in both the placebo and esketamine arms. Females also showed more pronounced reductions in the sadness and detachment factors at the end of the trials, as well as in the neurovegetative factor on day 15, regardless of treatment group. On the other hand, males showed a significant reduction in sadness symptoms after esketamine on day 2. These findings reveal that sex-assigned-at-birth influences overall antidepressant response and shapes the trajectory and symptom profile of improvement. Our findings emphasize the importance of incorporating sex-assigned-at-birth as a key variable to consider for optimizing TRD treatment strategies and advancing precision mental care.
引用
- Huc M, Siddiqi S, Myers M, et al. Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression. Mol Psychiatry. 2026. PMID: 41708888. doi:10.1038/s41380-026-03493-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。